OncoPharm

Discussing recent FDA approvals for expanded indications for trastuzumab-deruxtecan for gastric cancer (based on DESTINY-Gastric01) and SC daratumumab for AL amyloidosis. DESTINY-Gastric01: https://www.nejm.org/doi/full/10.1056/NEJMoa2004413

Our landmarks of OncoPharm series returns to discuss JBR10, adjuvant cisplatin/vinorelbine in NSCLC. JBR10: https://www.nejm.org/doi/pdf/10.1056/NEJMoa043623 JBR10 Update: https://pubmed.ncbi.nlm.nih.gov/19933915/ LACE meta-analysis: https://pubmed.ncbi.nlm.nih.gov/18506026/

This discussion unveils five significant FDA updates from December 2020, emphasizing pralcetinib's new role in RET-mutated medullary thyroid cancer. Delve into the clinical promise of HER2-targeting margituximab for breast cancer. Explore the safety of relugolix in hormone-sensitive prostate cancer treatments and recent advancements in selenexor and its Boston study. The intricate pharmacokinetics of new drugs also sheds light on tailored dosage strategies in oncology pharmacy.

Delve into the remarkable journey of trastuzumab, a game-changing cancer therapy stemming from the HER2 gene discovery. Discover how groundbreaking clinical trials and collaborations have paved the way for its use in breast cancer treatment, showcasing inspiring patient success stories. The discussion also highlights the drug's efficacy and safety, including potential risks like cardiomyopathy, ongoing monitoring strategies, and evolving treatment advancements for HER2-positive cases.

Highlighting some of the bright spots, oncopharm & otherwise, for our Holiday episode. Best new drug? Best study? Best movie to take my mind off of a pandemic? Enjoy this episode with a glass of Holiday Cheer.

COVID-19 Vaccines are here!!! Will they work in patients on chemo? What about immunotherapy? Without firm answers to such questions we might as well talk about mRNA vaccines, the breakout star of 2020.

First up we discuss RxPonder and what it adds to adjuvant treatment of breast cancer in the context of TailoRx. Then we discuss a recent study (https://jamanetwork.com/journals/jama/fullarticle/2774295)of additional capecitabine following adjuvant chemo in TNBC and what it adds in the context of CREATE-X.

Discover the latest breakthroughs in colon cancer treatment! The conversation highlights the final OS results of the IDEA trial, comparing 3 vs. 6 months of adjuvant chemotherapy. Also explored are the promising findings from the Keynote 177 trial, showcasing the effectiveness of Pembrolizumab for metastatic colorectal cancer with high microsatellite instability. Tune in for expert insights that could change the landscape of colon cancer care!

The Landmarks in OncoPharm series returns to discuss the practice-changing CLOT trial of a LMWH vs. a vitamin K antatogist for treating cancer-associated VTE. CLOT: https://www.nejm.org/doi/full/10.1056/nejmoa025313

Pembro gets an approval for triple negative breast cancer with quite high PD-L1 expression based on Keynote-355 (https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.1000). Some reassuring information on TKI discontinuation in CML from the LAST study (doi:10.1001/jamaoncol.2020.5774) and an interesting method of identifying predictors of TKI adherence in CML (https://journals.sagepub.com/doi/pdf/10.1177/1078155220970616).